Argus upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research note published on Tuesday, BenzingaRatingsTable reports. The brokerage currently has $430.00 price target on the biopharmaceutical company’s stock.
REGN has been the topic of a number of other research reports. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a report on Friday, February 7th. They set a hold rating and a $400.00 price target on the stock. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $360.00 price target on the stock in a report on Monday, November 11th. Oppenheimer raised their price target on shares of Regeneron Pharmaceuticals from to and gave the company an outperform rating in a report on Wednesday, January 22nd. Raymond James assumed coverage on shares of Regeneron Pharmaceuticals in a report on Monday, December 23rd. They set a market perform rating on the stock. Finally, Citigroup raised shares of Regeneron Pharmaceuticals from a neutral rating to a buy rating and raised their price target for the company from $340.00 to $420.00 in a report on Wednesday, November 6th. Thirteen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $394.30.
Shares of REGN stock opened at $399.55 on Tuesday. Regeneron Pharmaceuticals has a one year low of $271.37 and a one year high of $442.00. The company’s 50-day moving average is $370.46 and its 200 day moving average is $330.44. The company has a market capitalization of $43.87 billion, a price-to-earnings ratio of 21.64, a price-to-earnings-growth ratio of 1.06 and a beta of 1.24. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.46 and a current ratio of 2.84.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $7.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $6.03 by $1.47. The company had revenue of $2.17 billion for the quarter, compared to the consensus estimate of $2.10 billion. Regeneron Pharmaceuticals had a net margin of 26.91% and a return on equity of 24.14%. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the prior year, the firm posted $6.84 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals will post 22.34 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals declared that its board has initiated a share repurchase program on Tuesday, November 5th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy up to 2.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its stock is undervalued.
In related news, Chairman P Roy Vagelos sold 22,149 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $363.83, for a total value of $8,058,470.67. Also, VP Christopher R. Fenimore sold 1,682 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $376.14, for a total transaction of $632,667.48. Following the completion of the transaction, the vice president now directly owns 9,697 shares in the company, valued at approximately $3,647,429.58. The disclosure for this sale can be found here. In the last three months, insiders sold 104,679 shares of company stock worth $38,681,248. 11.84% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of REGN. Raymond James Trust N.A. raised its stake in Regeneron Pharmaceuticals by 3.4% during the 4th quarter. Raymond James Trust N.A. now owns 798 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 26 shares during the period. Zeke Capital Advisors LLC raised its stake in Regeneron Pharmaceuticals by 2.8% during the 4th quarter. Zeke Capital Advisors LLC now owns 1,263 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 34 shares during the period. Advisor Partners LLC raised its stake in Regeneron Pharmaceuticals by 5.1% during the 4th quarter. Advisor Partners LLC now owns 866 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 42 shares during the period. Cibc Bank USA raised its stake in Regeneron Pharmaceuticals by 3.5% during the 4th quarter. Cibc Bank USA now owns 1,480 shares of the biopharmaceutical company’s stock worth $556,000 after acquiring an additional 50 shares during the period. Finally, Banco Santander S.A. raised its stake in Regeneron Pharmaceuticals by 0.7% during the 4th quarter. Banco Santander S.A. now owns 7,400 shares of the biopharmaceutical company’s stock worth $2,779,000 after acquiring an additional 50 shares during the period. 66.42% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.